Peptide HPLC Certificate Explained — What UAE Researchers Should Check on Every COA
A peptide certificate of analysis (COA) is the single most important piece of paper in research-grade peptide purchasing — and the single most commonly faked. Generic or templated COAs are the norm in the grey market; lot-specific, instrument-traceable COAs are the exception. This guide walks what HPLC actually measures, why identity confirmation requires mass spectrometry separately from purity, and what UAE peptide researchers should actually check before reconstituting any vial — whether the supplier is REVIVE LAB or anyone else.
1. What HPLC actually is and what it measures
High Performance Liquid Chromatography (HPLC) is the standard analytical method for assessing peptide purity. A small sample of the peptide is dissolved, pushed through a chromatographic column under high pressure, and separated by interaction with the column's stationary phase. Different molecules travel through at different speeds and exit at different times. A UV detector at the column outlet records absorbance vs time — the resulting plot is the chromatogram.
Each peak in the chromatogram represents a distinct molecular species. The target peptide is the dominant peak. Smaller peaks are impurities — typically synthesis byproducts: truncated sequences (a peptide bond didn't form), deletion sequences (an amino acid was missed), oxidation products (methionine residues commonly oxidise), aggregation products.
HPLC purity = area of the target peptide peak / total chromatogram area, expressed as percentage. 98% HPLC purity means 98% of the absorbance area is the target peak. The remaining 2% is everything else.
2. Why HPLC alone is not enough
HPLC tells you the sample is mostly one molecule. It does not tell you which molecule. The peak with the highest area is the dominant species, but the chromatogram alone cannot confirm it's the molecule you ordered. A peptide can show 99% HPLC purity and be the wrong sequence — a different peptide of similar length and chemistry could chromatograph as a clean single peak.
This is why mass spectrometry is the separate identity-confirmation step. MS measures the molecular weight of the dominant peak directly. The theoretical molecular weight of any peptide is calculable from its sequence: sum of amino-acid residue masses + 18 (for the terminal water). MS-measured mass that matches theoretical mass (within ±0.5 Da for short peptides, ±1 Da for longer) confirms identity.
| Method | What it measures | What it doesn't |
|---|---|---|
| HPLC | Purity (% of dominant peak) | Identity of the peak |
| Mass spectrometry (MS) | Molecular weight of dominant species → identity | Quantitative purity |
| MALDI-TOF MS | Identity for medium/large peptides | Trace impurity detection |
| ESI-MS (LC-MS combined) | Identity + purity in one chromatogram | Higher equipment cost |
A proper research-peptide COA shows both HPLC purity AND MS identity confirmation. Either one alone is insufficient.
3. What a real lot-specific COA looks like
A lot-specific peptide COA contains specific, instrument-traceable elements. The standard fields:
- Product name: exact sequence name (e.g., "Retatrutide", "BPC-157", "GHK-Cu")
- Lot / batch number: unique identifier for this specific synthesis batch
- Synthesis date: when the batch was produced
- QC date: when analytical testing was performed (often within days of synthesis)
- Sequence (one-letter code): e.g., GEPPPGKPADDAGLV for BPC-157
- Theoretical molecular weight: calculated from sequence
- Measured molecular weight: from mass spec, with matching tolerance noted
- HPLC chromatogram image: showing the actual UV trace and the dominant peak
- HPLC purity percentage: with method conditions (column, mobile phase, gradient)
- MS spectrum image: showing the detected m/z peak(s)
- Analyst signature: or QA officer signature
- Appearance: typically "white to off-white lyophilised powder"
- Endotoxin level (optional): for in-vivo research grades
Templated COAs that have only a peptide name + "98%" with no chromatogram, no MS data, and no lot number are not COAs. They're marketing claims printed on letterhead.
4. Reading the HPLC chromatogram — what to actually look at
The chromatogram is a plot with time on the X axis (typically 0-30 minutes) and UV absorbance on the Y axis. Each peak is a separate molecule. What to check:
- Single dominant peak. The target peptide should produce one clear, tall peak. Multiple peaks of similar height indicate a mixture, not a pure peptide.
- Baseline before/after the peak. The trace should sit flat at zero absorbance before and after the peak. A noisy or drifting baseline can mask small impurity peaks.
- Peak shape. A clean peak is symmetric and sharp. Broad or asymmetric peaks (tailing) suggest the peptide is partially aggregated or the column is overloaded — neither inspires confidence.
- Minor peaks. Small peaks ahead of or behind the main peak are synthesis impurities — usually unavoidable but should be small relative to the main peak (typical: each <1% area).
- Retention time. Should match the certified value within ±5% — major shifts suggest column conditions or sample preparation differed from the certification run.
5. Reading the MS spectrum — what to actually look at
The mass spectrum is a plot with mass-to-charge (m/z) on the X axis and intensity on the Y axis. The main thing to verify is that the detected m/z value (with charge state corrected) matches the theoretical molecular weight of the peptide:
- For a +1 charge state: detected m/z = molecular weight + 1.0 (proton)
- For a +2 charge state: detected m/z = (molecular weight + 2.0) / 2
- Match tolerance: within ±0.5 Da for peptides <2 kDa; within ±1 Da for larger peptides
6. Common red flags on peptide COAs
- No batch number. Generic COA, not lot-specific. The supplier could be applying the same template to every vial regardless of batch.
- No MS data. Identity unconfirmed. Purity alone is insufficient.
- HPLC purity below 95%. Marginal for any modern peptide synthesis. Probably impurity-driven dose-response confounding.
- Multiple large peaks in chromatogram. Mixture, not pure peptide. Even at 98% stated purity, two peaks of comparable height contradict the claim.
- No analyst signature or QC date. COA may be templated or pre-printed.
- Refusal to provide COA on request. Major supplier red flag. A real research-grade supplier provides the COA in every parcel and on request.
- Photographs of paper documents instead of PDFs. Easier to fabricate. Legitimate suppliers issue digital PDF COAs traceable to the synthesis facility.
- Identical chromatograms across different products. Means the chromatogram is decorative, not real. Each peptide has a different retention time and peak shape.
7. The compounded GLP-1 grey market case study
The 2024-2026 compounded GLP-1 supply explosion in the UAE and globally has produced a specific COA-quality problem: many compounded semaglutide and tirzepatide products are reconstituted at non-stated concentrations, with COAs that show purity but not identity, and lot numbers that don't trace to specific synthesis batches. The Pew Research Trust and FDA have flagged this independently for the US compounding market.
For UAE researchers running comparison protocols, this matters specifically because compounded GLP-1 product is sometimes compared against retatrutide or branded semaglutide — and the comparison is only valid if both products are what their labels claim. We cover this issue more deeply in GLP-1 microdosing research 2026.
8. What REVIVE LAB UAE actually provides
REVIVE LAB UAE supplies every research peptide with a lot-specific HPLC + MS certificate of analysis. The format includes:
- Unique batch/lot number tied to the specific synthesis batch in our vial
- HPLC chromatogram image with the actual UV trace
- HPLC purity ≥98% on every batch (typically 98-99%)
- MS spectrum confirming theoretical molecular weight match
- Synthesis and QC dates
- Analyst/QA signature
- Appearance and reconstitution notes
The COA accompanies every parcel and is available on request via WhatsApp before purchase for researchers who want to review the lot-specific documentation. This is the documentation standard the entire peptides UAE catalogue ships with.
9. The summary
- HPLC measures purity. MS measures identity. Both required.
- Minimum acceptable HPLC purity for research-grade peptides: ≥95%; standard high quality: ≥98%.
- Lot-specific COA fields: batch number, sequence, theoretical MW, measured MW (MS), chromatogram image, purity %, dates, signature.
- Red flags: no lot number, no MS data, no chromatogram, generic templated docs, refusal to provide COA on request.
- Compounded GLP-1 grey-market product frequently lacks proper identity confirmation — researchers running comparisons should treat COAs as a primary quality signal.
- REVIVE LAB UAE supplies lot-specific HPLC + MS COA on every batch, ≥98% purity standard.
References
- Aebersold R, Mann M. Mass-spectrometric exploration of proteome structure and function. Nature. 2016;537(7620):347-355. PubMed
- Manning MC, Chou DK, Murphy BM, Payne RW, Katayama DS. Stability of protein pharmaceuticals: an update. Pharm Res. 2010;27(4):544-575. PubMed
- Vergote V, Burvenich C, Van de Wiele C, De Spiegeleer B. Quality specifications for peptide drugs: a regulatory-pharmaceutical approach. J Pept Sci. 2009;15(11):697-710. PubMed
- D'Hondt M, Bracke N, Taevernier L, et al. Related impurities in peptide medicines. J Pharm Biomed Anal. 2014;101:2-30. PubMed
- U.S. Food and Drug Administration. Drug Compounding: FDA Concerns Regarding Compounded Versions of GLP-1 Drugs. FDA.gov publication, 2024. FDA